Ripretinib FDA approval date

The FDA approved Ripretinib (DCC-2618) on 15 May 2020.

FDA approval date
15 May 2020

Drug identity checked against registry records

Also recorded as DCC-2618

Included trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2020-05-15DayRipretinibFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA213973", "applicant_as_listed_by_fda": "DECIPHERA PHARMS", "brand_names": ["QINLOCK"], "active_ingredients": ["RIPRETINIB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20200515", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026